B ristol Myers Squibb and SystImmune have announced breakthrough therapy designation from the US Food and Drug Administration ...

Lexeo Therapeutics Inc. (NASDAQ:LXEO) is one of the best IPO stocks to buy according to Wall Street analysts. Earlier on July ...

Recently, Professor An Chiying and her medical team at Shenzhen Hengsheng Hospital, China, announced a groundbreaking ...

The FDA designates iza-bren as a breakthrough therapy for advanced EGFR-mutant NSCLC, promising improved outcomes for ...

The FDA granted breakthrough therapy designation to Ifinatamab deruxtecan for some with extensive-stage small cell lung ...

The FDA has awarded Breakthrough Therapy Designation to izalontamab brengitecan, a potential first-in-class bispecific ...

Recent advancements in Merck's (MRK) product portfolio, including the FDA's Breakthrough Therapy Designation for ifinatamab deruxtecan and several approvals of their flagship drug KEYTRUDA, are ...

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to ifinatamab deruxtecan (I-DXd) for the treatment of adults with extensive-stage small cell lung cancer (ES-SCLC ...

FDA designates ifinatamab deruxtecan as a breakthrough therapy for extensive-stage small cell lung cancer, promising improved ...

The FDA has granted Breakthrough Therapy Designation to Bristol Myers Squibb (BMY) and SystImmune’s experimental drug iza-bren for treating advanced EGFR-mutant lung cancer after prior therapies fail, ...

Tel Aviv University announced on Wednesday that the surgery will take place in Israel, marking a historic milestone in ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ifinatamab deruxtecan for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) ...